ERBB2 and central nervous system neoplasm: Another phase I study evaluated the efficacy of autologous HER2-CAR-T cells in treating refractory or recurrent central nervous system tumors, examining the distribution of CAR-T cells in CSF, their migration into peripheral circulation, and the degree of HER2 expression at diagnosis versus recurrence.